File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study

TitleSignificant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study
Authors
Keywordschronic hepatitis B
fibroscan
liver stiffness
longitudinal
transient elastography
Issue Date2011
PublisherBlackwell Publishing Ltd. The Journal's website is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2893
Citation
Journal Of Viral Hepatitis, 2011, v. 18 n. 7, p. e200-e205 How to Cite?
AbstractFor patients with chronic hepatitis B (CHB) infection, changes in liver stiffness measurement (LSM) over time are not known. We examined changes longitudinally in a cohort of patients. Four hundred and twenty-six patients with CHB underwent transient elastography. Patients were followed regularly, and repeat elastography was performed at 3 years. Hepatitis serology, viral load and routine live r biochemistry were monitored. Of the 426 patients, 38 (9%) were hepatitis B e-antigen (HBeAg)-positive, 293 (69%) were HBeAg-negative and 95 (22%) were patients with prior hepatitis B surface antigen (HBsAg) seroclearance. A total of 110 patients received oral antiviral therapy. There was a significant decline of LSMs at the follow-up measurement compared to baseline (6.1 vs 7.8 kPa respectively, P = 0.002) in treated patients who had elevated alanine aminotransferase (ALT) at baseline and subsequent normalization after 3 years (normal ALT limit being 30 U/L for males and 19 U/L for females). In nontreated patients, only the patients with persistently normal ALT at both time points had significantly lower LSMs at the follow-up measurement compared to baseline: 4.9 vs 5.3 kPa, respectively, in patients who remained positive for HBsAg (P = 0.005) and 5.1 vs 5.4 kPa, respectively, in patients who had HBsAg seroclearance (P = 0.026). In patients who remained positive for HBsAg, independent factors associated with a significant decline in LSM of ≥1 kPa included antiviral therapy (P = 0.011) and the ALT levels at the follow-up time point (P = 0.024). Thus, in patients with CHB, a significant decline in LSM after 3 years was observed in treated patients with ALT normalization and in untreated patients who had persistently normal ALT. Antiviral therapy and follow-up ALT levels were independent significant factors associated with a decline in LSM. © 2011 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/137389
ISSN
2015 Impact Factor: 4.179
2015 SCImago Journal Rankings: 1.815
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFung, Jen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorSeto, WKen_HK
dc.contributor.authorHung, Ien_HK
dc.contributor.authorYuen, MFen_HK
dc.date.accessioned2011-08-26T14:24:14Z-
dc.date.available2011-08-26T14:24:14Z-
dc.date.issued2011en_HK
dc.identifier.citationJournal Of Viral Hepatitis, 2011, v. 18 n. 7, p. e200-e205en_HK
dc.identifier.issn1352-0504en_HK
dc.identifier.urihttp://hdl.handle.net/10722/137389-
dc.description.abstractFor patients with chronic hepatitis B (CHB) infection, changes in liver stiffness measurement (LSM) over time are not known. We examined changes longitudinally in a cohort of patients. Four hundred and twenty-six patients with CHB underwent transient elastography. Patients were followed regularly, and repeat elastography was performed at 3 years. Hepatitis serology, viral load and routine live r biochemistry were monitored. Of the 426 patients, 38 (9%) were hepatitis B e-antigen (HBeAg)-positive, 293 (69%) were HBeAg-negative and 95 (22%) were patients with prior hepatitis B surface antigen (HBsAg) seroclearance. A total of 110 patients received oral antiviral therapy. There was a significant decline of LSMs at the follow-up measurement compared to baseline (6.1 vs 7.8 kPa respectively, P = 0.002) in treated patients who had elevated alanine aminotransferase (ALT) at baseline and subsequent normalization after 3 years (normal ALT limit being 30 U/L for males and 19 U/L for females). In nontreated patients, only the patients with persistently normal ALT at both time points had significantly lower LSMs at the follow-up measurement compared to baseline: 4.9 vs 5.3 kPa, respectively, in patients who remained positive for HBsAg (P = 0.005) and 5.1 vs 5.4 kPa, respectively, in patients who had HBsAg seroclearance (P = 0.026). In patients who remained positive for HBsAg, independent factors associated with a significant decline in LSM of ≥1 kPa included antiviral therapy (P = 0.011) and the ALT levels at the follow-up time point (P = 0.024). Thus, in patients with CHB, a significant decline in LSM after 3 years was observed in treated patients with ALT normalization and in untreated patients who had persistently normal ALT. Antiviral therapy and follow-up ALT levels were independent significant factors associated with a decline in LSM. © 2011 Blackwell Publishing Ltd.en_HK
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's website is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2893en_US
dc.relation.ispartofJournal of Viral Hepatitisen_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.comen_US
dc.subjectchronic hepatitis Ben_HK
dc.subjectfibroscanen_HK
dc.subjectliver stiffnessen_HK
dc.subjectlongitudinalen_HK
dc.subjecttransient elastographyen_HK
dc.subject.meshAlanine Transaminase - blood-
dc.subject.meshElasticity Imaging Techniques-
dc.subject.meshHepatitis B e Antigens - blood-
dc.subject.meshHepatitis B, Chronic - blood - drug therapy - virology-
dc.subject.meshLiver - pathology-
dc.titleSignificant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up studyen_HK
dc.typeArticleen_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailSeto, WK: wkseto2@hku.hken_HK
dc.identifier.emailHung, I: ivanhung@hkucc.hku.hken_HK
dc.identifier.emailYuen, MF: mfyuen@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authoritySeto, WK=rp01659en_HK
dc.identifier.authorityHung, I=rp00508en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1365-2893.2010.01428.xen_HK
dc.identifier.pmid21692933-
dc.identifier.scopuseid_2-s2.0-79959611340en_HK
dc.identifier.hkuros189868en_US
dc.identifier.hkuros211270-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79959611340&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume18en_HK
dc.identifier.issue7en_HK
dc.identifier.spagee200en_HK
dc.identifier.epagee205en_HK
dc.identifier.isiWOS:000292265400006-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridFung, J=55032286400en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridWong, DKH=7401535819en_HK
dc.identifier.scopusauthoridSeto, WK=23390675900en_HK
dc.identifier.scopusauthoridHung, I=7006103457en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats